Close
Close

The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)

Disease Information

Descriptive Information
Brief Title † The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)
Official Title † Effect of Bezafibrate on Very Long Chain Fatty Acid Metabolism in Men With X-linked Adrenoleukodystrophy (X-ALD)
Brief Summary X-linked adrenoleukodystrophy (X-ALD) is an inherited metabolic disorder characterised by accumulation of very long chain fatty acids (VLCFA) in plasma and tissue. Presumably this accumulation is responsible for tissue damage. The disease can cause severe demyelinisation of the central nervous system usually causing death in childhood or progressive ambulatory problems in adults caused by a progressive myelopathy. For the latter category of patients no curative treatment is currently available. Recent investigations in human fibroblasts and mice identified bezafibrate as an agent that might reduce VLCFA in patients with X-ALD. Objective of the study: The trial is designed as an open-label pilot study. The main goal is to investigate if bezafibrate can reduce VLCFA in vivo in patient with X-ALD. If there is indeed a biochemical effect, a large follow-up study will be initiated with clinical outcome parameters. Study design: 10 men with X-ALD will use bezafibrate during a period of 6 months (in combination with a low fat diet). On 6 different time points the participants will undergo a venipuncture for detecting possible side effects and to determine the biochemical outcome parameters. Study population: Adult men with X-linked adrenoleukodystrophy. Intervention (if applicable): Bezafibrate. Primary study parameters/outcome of the study: The primary outcome parameters are cholesterol levels (total-, LDL, and HDL) and levels of triglycerides in plasma, VLCFA levels in plasma, leukocytes and erythrocytes and also C26:0-lyso-PC in bloodspots. Secondary study parameters/outcome of the study (if applicable): Secondary outcome parameters are side-effects (subjective and abnormalities in the safety lab).
Detailed Description
Study Phase N/A
Study Type † Interventional
Study Design † Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary Outcome Measure † Very long chain fatty acids (VLCFA; C22:0, C24:0 and C26:0) in plasma, lymphocytes and erythrocytes.
Secondary Outcome Measure † Side effects
Condition † X-linked Adrenoleukodystrophy Adrenomyeloneuropathy
Intervention † DrugBezafibrate
Study Arms / Comparison Groups Bezafibrate All patients in the trial will use bezafibrate 400 mg once daily until week 12, and subsequently use 800 mg onde daily until week 24.
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Drug
Estimated Enrollment † 10
Start Date † July 2010
Completion Date August 2011
Primary Completion Date August 2011
Eligibility Criteria † Inclusion Criteria: - an age of 18 years or older - capable of giving informed consent and capable of visiting the hospital for follow-up visits - no contra-indications for the use of bezafibrate, e.g. kidney- and/or liver disease. - confirmed X-ALD, AMN phenotype (confirmed by VLCFA analysis or analysis of the ABCD1 gene) Exclusion Criteria: - use of medication that lowers cholesterol and/or triglycerides (e.g. statins) - liver disease or and increase in serum CK of more than 3 times the baseline level - treatment with Lorenzo's oil in the 8 weeks preceding the trial
Gender Male
Ages 18 Years - N/A
Accepts Healthy Volunteers No
Contacts ††
Location Countries † Netherlands
Administrative Information
NCT ID † NCT01165060
Organization ID MEC 09/278
Secondary IDs ††
Responsible Party
Study Sponsor † Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators †† The Stop ALD Foundation
Investigators † Principal Investigator: Bwee Tien Poll - The, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Information Provided By
Verification Date July 2010
First Received Date † July 13, 2010
Last Updated Date August 9, 2011
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
Free Newsletter